{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:13:31Z","timestamp":1779214411191,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["RS-2024-00335179"],"award-info":[{"award-number":["RS-2024-00335179"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["RS-2024-00335179"],"award-info":[{"award-number":["RS-2024-00335179"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["RS-2024-00335179"],"award-info":[{"award-number":["RS-2024-00335179"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["RS-2024-00335179"],"award-info":[{"award-number":["RS-2024-00335179"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["RS-2024-00335179"],"award-info":[{"award-number":["RS-2024-00335179"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    PG-102 is a potency-optimized bispecific Fc fusion protein targeting GLP-1 and GLP-2 receptors. In\n                    <jats:italic>db\/db<\/jats:italic>\n                    mouse models of advanced diabetes characterized by uncontrolled hyperglycemia and catabolic weight loss, PG-102 achieved superior and sustained glycemic control compared with semaglutide or tirzepatide while preserving body weight, uncoupling glycemic control from catabolic weight loss. Mechanistic studies indicated that these effects were not driven by acute insulinotropic activity, but by \u03b2-cell preservation and enhanced glucose uptake. These benefits required dual GLP-1R\/GLP-2R engagement, as PG-102 outperformed monospecific Fc fusion agonists or their combination and promoted coordinated receptor trafficking with delayed internalization. We conducted a randomized, double-blind, placebo-controlled multiple ascending dose phase 1 study at a single center in the Republic of Korea in adults with overweight (BMI 25\u201330\u2009kg\/m\u00b2). Twenty-four participants were randomized within three weekly dose cohorts (15\u2009mg, 30\u2009mg, and 30\/60\u2009mg;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20096 per cohort) in a 6:2 ratio to receive PG-102 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200918) or placebo (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20096). All randomized participants (PG-102\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200918; placebo\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20096) received at least one dose and were included in the safety analysis. Safety and tolerability were predefined as the primary endpoint and assessed by treatment-emergent adverse events (TEAEs). TEAEs occurred in 5\/6 (83.3%) participants in each PG-102 cohort and 4\/6 (66.7%) in placebo; treatment-related AEs occurred in 5\/6 (83.3%) and 3\/6 (50.0%), respectively. No serious adverse events or discontinuations due to adverse events occurred. Gastrointestinal events were mild to moderate. These findings support bispecific GLP-1\/GLP-2 agonism as a mechanistically distinct incretin strategy in advanced T2D. ClinicalTrials.gov identifier: NCT06309667.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-71080-0","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:49:09Z","timestamp":1774360149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bispecific GLP-1\/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-6508","authenticated-orcid":false,"given":"Sang-In","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0395-2026","authenticated-orcid":false,"given":"Sae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4778-9610","authenticated-orcid":false,"given":"Kyung-Hwa","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9192-2849","authenticated-orcid":false,"given":"Seung-Ah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Gyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Il","family":"Roh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2726-907X","authenticated-orcid":false,"given":"Young Chul","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"71080_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng, Z. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct. Target Ther. 9, 234 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"71080_CR2","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1111\/dom.15038","volume":"25","author":"H Jung","year":"2023","unstructured":"Jung, H. et al. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: a retrospective analysis of the Diabetes Prospective Follow-Up Registry. Diab. Obes. Metab. 25, 1813\u20131822 (2023).","journal-title":"Diab. Obes. Metab."},{"key":"71080_CR3","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2147\/PPA.S277676","volume":"14","author":"T Weiss","year":"2020","unstructured":"Weiss, T. et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Patient Prefer Adherence 14, 2337\u20132345 (2020).","journal-title":"Patient Prefer Adherence"},{"key":"71080_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/DMSO.S141235","volume":"10","author":"MV Sikirica","year":"2017","unstructured":"Sikirica, M. V. et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diab. Metab. Syndr. Obes. 10, 403\u2013412 (2017).","journal-title":"Diab. Metab. Syndr. Obes."},{"key":"71080_CR5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/jcsm.12553","volume":"11","author":"WC Liao","year":"2020","unstructured":"Liao, W. C. et al. Relationship between pancreatic cancer-associated diabetes and cachexia. J. Cachexia Sarcopenia Muscle 11, 899\u2013908 (2020).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"71080_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/nu16010172","volume":"16","author":"JM Lopez-Pedrosa","year":"2024","unstructured":"Lopez-Pedrosa, J. M. et al. The vicious cycle of type 2 diabetes mellitus and skeletal muscle atrophy: clinical, biochemical, and nutritional bases. Nutrients 16, 172 (2024).","journal-title":"Nutrients"},{"key":"71080_CR7","first-page":"94","volume":"22","author":"BD Perry","year":"2016","unstructured":"Perry, B. D. et al. Muscle atrophy in patients with type 2 diabetes mellitus: roles of inflammatory pathways, physical activity and exercise. Exerc Immunol. Rev. 22, 94\u2013109 (2016).","journal-title":"Exerc Immunol. Rev."},{"key":"71080_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.peptides.2017.07.011","volume":"95","author":"D Khan","year":"2017","unstructured":"Khan, D., Vasu, S., Moffett, R. C., Irwin, N. & Flatt, P. R. Differential expression of glucagon-like peptide-2 (GLP-2) is involved in pancreatic islet cell adaptations to stress and beta-cell survival. Peptides 95, 68\u201375 (2017).","journal-title":"Peptides"},{"key":"71080_CR9","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.3390\/biom14121520","volume":"14","author":"A Ali","year":"2024","unstructured":"Ali, A. et al. Comparative effects of GLP-1 and GLP-2 on beta-cell function, glucose homeostasis and appetite regulation. Biomolecules 14, 1520 (2024).","journal-title":"Biomolecules"},{"key":"71080_CR10","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1111\/bph.15278","volume":"178","author":"M Ejarque","year":"2021","unstructured":"Ejarque, M. et al. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function. Br. J. Pharm. 178, 2131\u20132145 (2021).","journal-title":"Br. J. Pharm."},{"key":"71080_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.697120","volume":"12","author":"W He","year":"2021","unstructured":"He, W. et al. GLP-2 is locally produced from human islets and balances inflammation through an inter-islet-immune cell crosstalk. Front. Endocrinol. 12, 697120 (2021).","journal-title":"Front. Endocrinol."},{"key":"71080_CR12","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/hep.32235","volume":"75","author":"ER Kim","year":"2022","unstructured":"Kim, E. R. et al. A GLP-1\/GLP-2 receptor dual agonist to treat NASH: targeting the gut-liver axis and microbiome. Hepatology 75, 1523\u20131538 (2022).","journal-title":"Hepatology"},{"key":"71080_CR13","doi-asserted-by":"publisher","first-page":"e24574","DOI":"10.1371\/journal.pone.0024574","volume":"6","author":"SJ Im","year":"2011","unstructured":"Im, S. J. et al. Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin. PLoS ONE 6, e24574 (2011).","journal-title":"PLoS ONE"},{"key":"71080_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","volume":"9","author":"U Brinkmann","year":"2017","unstructured":"Brinkmann, U. & Kontermann, R. E. The making of bispecific antibodies. MAbs 9, 182\u2013212 (2017).","journal-title":"MAbs"},{"key":"71080_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1042\/BST0350713","volume":"35","author":"R Mann","year":"2007","unstructured":"Mann, R. et al. Peptide binding at the GLP-1 receptor. Biochem. Soc. Trans. 35, 713\u2013716 (2007).","journal-title":"Biochem. Soc. Trans."},{"key":"71080_CR16","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1210\/er.2014-1035","volume":"35","author":"EE Mulvihill","year":"2014","unstructured":"Mulvihill, E. E. & Drucker, D. J. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr. Rev. 35, 992\u20131019 (2014).","journal-title":"Endocr. Rev."},{"key":"71080_CR17","doi-asserted-by":"publisher","first-page":"54178","DOI":"10.1039\/C7RA10822B","volume":"7","author":"L Lu","year":"2017","unstructured":"Lu, L. et al. In vitro and in vivo characterization of a novel long-acting GLP-1 receptor agonist, exendin-4\u2013Fc fusion protein. RSC Adv. 7, 54178\u201354187 (2017).","journal-title":"RSC Adv."},{"key":"71080_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/jmr.2154","volume":"25","author":"AE Baker","year":"2012","unstructured":"Baker, A. E. et al. The dimerization of glucagon-like peptide-2 MIMETIBODY is linked to leucine-17 in the glucagon-like peptide-2 region. J. Mol. Recognit. 25, 155\u2013164 (2012).","journal-title":"J. Mol. Recognit."},{"key":"71080_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5625\/lar.2015.31.1.1","volume":"31","author":"HM Choi","year":"2015","unstructured":"Choi, H. M. et al. An age-dependent alteration of the respiratory exchange ratio in the db\/db mouse. Lab Anim. Res. 31, 1\u20136 (2015).","journal-title":"Lab Anim. Res."},{"key":"71080_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2337\/diabetes.54.3.687","volume":"54","author":"S Schneider","year":"2005","unstructured":"Schneider, S. et al. Long-term graft function of adult rat and human islets encapsulated in novel alginate-based microcapsules after transplantation in immunocompetent diabetic mice. Diabetes 54, 687\u2013693 (2005).","journal-title":"Diabetes"},{"key":"71080_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun, T. et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol. Metab. 18, 3\u201314 (2018).","journal-title":"Mol. Metab."},{"key":"71080_CR22","doi-asserted-by":"crossref","unstructured":"Ma, T. et al. Distinct effects of semaglutide and tirzepatide on metabolic and inflammatory gene expression in brown adipose tissue of mice fed a high-fat, high-fructose diet. Front. Nutr. 12, 1659233 (2025).","DOI":"10.3389\/fnut.2025.1659233"},{"key":"71080_CR23","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1038\/s41366-020-00657-6","volume":"44","author":"B Chanclon","year":"2020","unstructured":"Chanclon, B. et al. Peripancreatic adipose tissue protects against high-fat-diet-induced hepatic steatosis and insulin resistance in mice. Int. J. Obes. 44, 2323\u20132334 (2020).","journal-title":"Int. J. Obes."},{"key":"71080_CR24","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1016\/j.bbadis.2018.07.024","volume":"1864","author":"SA Rebuffat","year":"2018","unstructured":"Rebuffat, S. A. et al. Adipose tissue derived-factors impaired pancreatic beta-cell function in diabetes. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 3378\u20133387 (2018).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"71080_CR25","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s42255-023-00811-0","volume":"5","author":"K El","year":"2023","unstructured":"El, K. et al. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nat. Metab. 5, 945\u2013954 (2023).","journal-title":"Nat. Metab."},{"key":"71080_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos, T. D., Panagiotopoulou, T. V. & Elisaf, M. S. Adverse effects of GLP-1 receptor agonists. Rev. Diabet. Stud. 11, 202\u2013230 (2014).","journal-title":"Rev. Diabet. Stud."},{"key":"71080_CR27","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.21037\/atm.2018.11.15","volume":"6","author":"M Abdul-Ghani","year":"2018","unstructured":"Abdul-Ghani, M. & DeFronzo, R. Therapeutic strategies for type 2 diabetes mellitus patients with very high HbA1c: is insulin the only option? Ann. Transl. Med. 6, S95 (2018).","journal-title":"Ann. Transl. Med."},{"key":"71080_CR28","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck, M. A., Quast, D. R., Wefers, J. & Meier, J. J. GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art. Mol. Metab. 46, 101102 (2021).","journal-title":"Mol. Metab."},{"key":"71080_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","volume":"21","author":"MA Nauck","year":"2022","unstructured":"Nauck, M. A. & D\u2019Alessio, D. A. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc. Diabetol. 21, 169 (2022).","journal-title":"Cardiovasc. Diabetol."},{"key":"71080_CR30","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1210\/en.2019-00398","volume":"160","author":"B Yusta","year":"2019","unstructured":"Yusta, B. et al. Localization of glucagon-like peptide-2 receptor expression in the mouse. Endocrinology 160, 1950\u20131963 (2019).","journal-title":"Endocrinology"},{"key":"71080_CR31","doi-asserted-by":"publisher","first-page":"703966","DOI":"10.3389\/fcell.2021.703966","volume":"9","author":"NM Morrow","year":"2021","unstructured":"Morrow, N. M., Hanson, A. A. & Mulvihill, E. E. Distinct identity of GLP-1R, GLP-2R, and GIPR expressing cells and signaling circuits within the gastrointestinal tract. Front. Cell Dev. Biol. 9, 703966 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"71080_CR32","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1053\/gast.2000.16489","volume":"119","author":"B Yusta","year":"2000","unstructured":"Yusta, B. et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 119, 744\u2013755 (2000).","journal-title":"Gastroenterology"},{"key":"71080_CR33","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1210\/en.2011-1070","volume":"152","author":"J Vendrell","year":"2011","unstructured":"Vendrell, J. et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology 152, 4072\u20134079 (2011).","journal-title":"Endocrinology"},{"key":"71080_CR34","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.chembiol.2024.07.004","volume":"31","author":"RC Oslund","year":"2024","unstructured":"Oslund, R. C., Holland, P. M., Lesley, S. A. & Fadeyi, O. O. Therapeutic potential of cis-targeting bispecific antibodies. Cell Chem. Biol. 31, 1473\u20131489 (2024).","journal-title":"Cell Chem. Biol."},{"key":"71080_CR35","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S0301-472X(01)00611-7","volume":"29","author":"JB Monahan","year":"2001","unstructured":"Monahan, J. B. et al. Bivalent binding and signaling characteristics of Leridistim, a novel chimeric dual agonist of interleukin-3 and granulocyte colony-stimulating factor receptors. Exp. Hematol. 29, 416\u2013424 (2001).","journal-title":"Exp. Hematol."},{"key":"71080_CR36","unstructured":"Chao, J. H. & Hirsch, I. B. Initial management of severe hyperglycemia in type 2 diabetes. in Endotext (eds. Feingold, K. R. et al.) (South Dartmouth, 2000)."},{"key":"71080_CR37","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey, W. T. et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat. Med. 28, 2083\u20132091 (2022).","journal-title":"Nat. Med."},{"key":"71080_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2024.105462","volume":"124","author":"YL Ye","year":"2024","unstructured":"Ye, Y. L. et al. GLP-2 ameliorates D-galactose induced muscle aging by IGF-1\/Pi3k\/Akt\/FoxO3a signaling pathway in C2C12 cells and mice. Arch. Gerontol. Geriatr. 124, 105462 (2024).","journal-title":"Arch. Gerontol. Geriatr."},{"key":"71080_CR39","volume":"4","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Gut microbiota in muscular atrophy development, progression, and treatment: New therapeutic targets and opportunities. Innovation 4, 100479 (2023).","journal-title":"Innovation"},{"key":"71080_CR40","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/gut.2008.165886","volume":"58","author":"PD Cani","year":"2009","unstructured":"Cani, P. D. et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091\u20131103 (2009).","journal-title":"Gut"},{"key":"71080_CR41","doi-asserted-by":"crossref","unstructured":"Koide, Y. et al. Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: a multicenter prospective observational study. Front. Clin. Diabetes Healthc 6, 1638681 (2025).","DOI":"10.3389\/fcdhc.2025.1638681"},{"key":"71080_CR42","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.clnu.2018.07.030","volume":"38","author":"S Pevny","year":"2019","unstructured":"Pevny, S. et al. Experience with teduglutide treatment for short bowel syndrome in clinical practice. Clin. Nutr. 38, 1745\u20131755 (2019).","journal-title":"Clin. Nutr."},{"key":"71080_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.nut.2018.06.007","volume":"57","author":"L Xiao","year":"2019","unstructured":"Xiao, L. et al. Vitamin A supplementation improves the intestinal mucosal barrier and facilitates the expression of tight junction proteins in rats with diarrhea. Nutrition 57, 97\u2013108 (2019).","journal-title":"Nutrition"},{"key":"71080_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.688715","volume":"8","author":"G Deng","year":"2021","unstructured":"Deng, G. et al. Glucagon-like peptide-2 modulates enteric paneth cells immune response and alleviates gut inflammation during intravenous fluid infusion in mice with a central catheter. Front. Nutr. 8, 688715 (2021).","journal-title":"Front. Nutr."},{"key":"71080_CR45","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1038\/ctg.2015.69","volume":"7","author":"LK Schwartz","year":"2016","unstructured":"Schwartz, L. K. et al. Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clin. Transl. Gastroenterol. 7, e142 (2016).","journal-title":"Clin. Transl. Gastroenterol."},{"key":"71080_CR46","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.ajcnut.2023.02.015","volume":"117","author":"B de Dreuille","year":"2023","unstructured":"de Dreuille, B. et al. Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring. Am. J. Clin. Nutr. 117, 1143\u20131151 (2023).","journal-title":"Am. J. Clin. Nutr."},{"key":"71080_CR47","doi-asserted-by":"crossref","unstructured":"Tair, K. A. & Hakimian, D. Long-term gastrointestinal outcomes in patients on teduglutide: a propensity-matched analysis. Intest. Fail. 6, 100073 (2025).","DOI":"10.1016\/j.intf.2025.100081"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71080-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71080-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71080-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:02:44Z","timestamp":1779213764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71080-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71080"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71080-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.C.S. and S.Y. are inventors on patents related to this work (PCT\/KR2021\/003127 & PCT\/KR2021\/003128). Y.C.S. is a current employee of SL BiGen, Inc. S.I. is a former employee of SL BiGen, Inc. and now a current employee of ProGen Co., Ltd. J.R. is a former employee of both SL BiGen, Inc. and ProGen Co., Ltd. S.W.K., K.S., S.L., and J.K. are current employees of ProGen Co., Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4477"}}